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Testosterone is a steroidal male hormone that regulates cellular calcium transport
(1). It is useful in preventing osteoporosis and coronary artery diseases (2), in suppress-
ing diverse immune reactions (3) and in gerontology (4). Free testosterone is also emerg-
ing as a significant possibility in life quality improvements for HIV patients (5). Health
implications of testosterone and also its large-scale use by athletes have propelled stud-
ies on different modified drug delivery systems for testosterone (6).
The drug testosterone, however, is practically insoluble in water, has a relatively short
plasma half-life of about 10–20 minutes (7–9) and the drug as such undergoes extensive
first pass metabolism in liver (10). Transdermal patches of testosterone are available but
must be applied to scrotal skin to achieve some therapeutic levels (11). In view of several
pharmacokinetic limitations of the natural hormone and its increasing multivarious thera-
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Slow release testosterone-loaded nanocapsules in alginate,
biodegradable hydropolymer, were prepared by in situ
nanoemulsion-polymer crosslinking approach. Different
formulations varying in the drug loading solvent phase
were prepared. Four different drug-loading solvents were
assayed and the food grade hexane provided nanocap-
sules testosterone load of 30%. Testosterone loading was
confirmed by FT-IR, DSC and quantitated by HPLC. Pre-
pared nanocapsules appeared spherical with a dense drug
core in transmission electron microscopy studies. Hydro-
dynamic diameter of nanocapsules was 34.5 ± 1.7 nm,
with a Gaussian distribution and the zeta potential –5.0
meV. Sustained diffusive drug release was observed in
vitro, following zero order kinetics releasing the drug
payload over a period of 48 hours. Embedding testoster-
one in alginate provided sustained release. Different drug
loading solvents have distinct influence on drug loading
and nanocapsules size distribution. The nanocapsulation
technique developed can be a good choice for the deve-
lopment of different sustained steroid hormonal drug car-
riers.
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peutic requirements, a suitable slow release testosterone loaded nanocapsules (NCs) in
biodegradable material was perceived.
NCs within a certain size range are known to be easily circulating, passing even
through small capillaries without clogging (12). Selection of a suitable biodegradable
and biocompatible polymeric coating material was found to provide protection of the
bioactive hormone molecule within the polymeric coating, releasing the drug load in a
definitive and sustained release manner.
Pursuing these objectives, this work was aimed at developing a suitable slow re-
lease testosterone NC formulation using hydrobased polymer material, alginate, follow-
ing a nanoemulsion and polymer cross-linking approach. Different drug encapsulating
solvents were used in order to evaluate the resultant drug payload, size distribution and
to arrive at a suitable slow release testosterone NCs formulation.
EXPERIMENTAL
Materials
Sodium alginate (viscosity 250 cps, 2% m/V in water) was purchased from Sigma
Chemicals (USA). Testosterone was obtained as a gift from Organon India Limited (In-
dia). All organic solvents and water used were of high performance liquid chromatogra-
phy (HPLC) grade (Merck/Spectrochem, India). All other reagents of analytical grade
were procured from Merck or Spectrochem and used as received.
Preparation of testosterone-loaded alginate nanocapsules
Testosterone was encapsulated in calcium alginate by the in situ nanoemulsification-
-polymer cross-linking method (Fig. 1). Thus, 5 mg of the drug, testosterone, was taken in
10 mL of different drug loading solvents and emulsified under sonication at 20 kHz in 30
mL of 0.1% m/V aqueous solution of sodium alginate, using polyoxyethylene sorbitan
mono-oleate (Tween 80) as emulsifier. Stabilizer, glycerol (30 mL), was then added drop-
wise to produce the nanoemulsion. Calcium chloride solution (2 mol L–1, 1.5 mL) was
added into the reaction mixture to effect cross-linking of the NCs produced. The reaction
mixture was cured for 24 h at room temperature (25 °C). NCs were then separated by ultra
centrifugation (Sorvall Ultra 80, Sorvall, USA) at 30,000 rpm, 0 °C, 30 min. NCs thus ob-
tained were washed with 15 mL of water, recentrifuged and harvested in micro centrifuge
tubes. These were then preserved in vacuum desiccators at 4 °C for further evaluations.
The drug to polymer ratio (D:P) used in all cases was 1:6 (m/m) and a series of batches
were prepared using four different drug loading solvents, viz., hexane (food grade), ethyl
acetate, dichloromethane and 1,2-dichloroethane to optimize drug loading.
Characterization of nanocapsules
Particle size distribution in PCS. – The particle size and size distribution of the pre-
pared NCs were measured using Photon Correlation Spectroscopy, PCS (Zetasizer 1000HS,
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Malvern Instruments, UK) with a 4 mW He–Ne laser beam at a wavelength of 633 nm at
25 °C and at a scattering angle of 90°. Aliquots from each preparation batch were sam-
pled in PCS cuvettes and NCs were then examined for equivalent diameters, size distri-
bution and polydispersity.
Size distribution in TEM. – Transmission electron microscopy, TEM (FEI Technai 12
BioTwin, The Netherlands) with a CCD camera Megaview III soft imaging system was
employed to visualize and record the nature and the size distribution of NCs. A general-
ized protocol was used for TEM studies. A drop of water suspension of the NCs was
mounted on a carbon coated copper grid (CCG) and air-dried. NCs were stained with
2% uranyl acetate after washing with buffer solution (pH 4.0, phosphate) and micro graph-
ed at 80–100 kV.
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Fig. 1. Schematic representation of the preparation of nanocapsules
(in situ nanoemulsion-polymer crosslinking method).
Drug loading. – Reverse phase HPLC method was used to determine the total en-
trapment of testosterone. The HPLC set-up consisted of LC-6A, Shimadzu system (Ja-
pan) with a UV-Vis detector. Testosterone concentrations were determined using an ODS
column (Zorbax-ODS, Agilent, USA) and methanol/water mobile phase in the ratio 80:20
at a flow rate of 0.5 mL min–1. Eluates were monitored at a fixed max of 239 nm. A 20 L
sample volume was injected each time through a Rheodyne injector. HPLC elution time
for testosterone was 12 minutes.
A standard curve was first prepared using known concentrations of standard testos-
terone against the HPLC peak area and was used throughout for analysis. Standard curve
equation was y = 5.32 × 106  + 686.03, R2 = 0.9998 (y = HPLC peak area,  = concentra-
tion in mg mL–1, R = correlation coefficient).
About 20 mg accurately weighed testosterone NCs were digested in 40 mL of 1%
m/V sodium citrate solution and the final volume was made up to 50 mL with deionized
water. The mixture was sonicated at 20 kHz for 30 minutes and the solution was filtered
using centricon tubes (molecular mass cut off 50,000) in a cold centrifuge (Remi C30, In-
dia) at 0 °C, 10,000 rpm. 20 L of filtrate was injected into HPLC. Six samples from each
batch were analyzed.
Zeta potential. – Zeta potential was measured for each formulation batch using large
bore capillary cells in the Zetasizer Nano-ZS (Malvern Instruments). One mL of NCs sus-
pension from the preparation medium was sampled out and diluted to 8 mL with 0.9%
(m/V) NaCl solution prepared in HPLC water for optimal signal intensity (13). The pH
of the water used was 6.0 ± 0.1. Six samples of each batch were recorded to get the aver-
age zeta potential for different formulations.
Differential scanning calorimetry. – NC thermograms were studied using a differential
scanning calorimeter (DSC-60, Shimadzu). Two mg samples of NCs were heated from 20
to 400 °C in crimped aluminum pans to produce thermograms at a heating rate of 10 °C
min–1. Alumina (2.0 mg) in crimped aluminum pans supplied by the instrument manu-
facturer was used as the standard reference material to calibrate the temperature and en-
ergy scales.
Fourier transformed-infrared spectra. – FT-IR spectra (FTIR 670, Jasco, Japan) of testos-
terone, testosterone loaded NCs and sodium alginate were recorded in potassium bro-
mide pellets. Testosterone powder was mixed with dried and ground potassium bro-
mide (E. Merck, FT-IR grade), pelletized at 10.3 × 104 Pa and the spectrum was recorded
between 4000–400 cm–1 using a high-energy ceramic source and DLATGS detectors.
Similarly, the NCs prepared and the sodium alginate powder were analyzed by FT-IR
and compared using the Biorad knowItAll(tm) informatics system software (Biorad Lab-
oratories, USA) for spectral analysis.
In-vitro drug release. – About 20.0 mg of accurately weighed NCs were taken in 30
mL of 100 mmol L–1 phosphate buffer (pH = 7.4) containing 5% V/V methanol. The re-
lease studies were carried out at 37 °C under continuous stirring at 50 rpm and cumula-
tive drug release was measured under sink conditions. 0.1 mL aliquots were sampled
out at regular time intervals, filtered in centricon tubes (molecular mass cut-off 50,000)
and 20 L was injected into the HPLC column. The samples withdrawn were replaced
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each time with 1 mL of fresh buffer mixture. HPLC analysis conditions were as describ-
ed earlier and the standard curve similarly prepared was used for data analysis with
necessary corrections for the dilution factors.
RESULTS AND DISCUSSION
Testosterone loaded alginate NCs were prepared following oil in water nanoemul-
sion and in situ polymer crosslinking. Four different formulations were designed (Table
I) using different drug loading solvents with differing dielectric constants, such as food
grade hexane (, 1.89), ethyl acetate (, 6.02), dichloromethane (, 9.08) and 1,2-dichloro-
ethane (, 10.36) (14). Different drug loading solvents have shown a distinct impact on
the drug payloading and nanocapsular size distribution.
Both the size and size distribution can strongly influence nanocapsular drug deli-
very (12). Particular drug carriers of an average diameter less than 10 nm in circulation
are rapidly removed through extravation and renal clearance while particles ranging
from 10–70 nm are the most effective systems for tissue distribution since they can circu-
late even in small capillaries and be taken up in tissues (15). Larger particles of diameter
200 nm are normally removed in phagocytosis and by the spleen as a result of mechani-
cal filtration (16). Size distributions for all formulations were studied in PCS and the
mean PCS diameters (Table II) were directly recorded as intensity-weighted.
PCS size distributions of formulation A provided a Gaussian size distribution with
an average nanocapsular diameter of 34.5 nm (Fig. 2). Size distribution in formulation B
was partially skewed, average diameter was 34.8 nm. Formulation C and formulation D
produced larger particles of average PCS diameters of 585.2 nm and 819.8 nm, respec-
tively. The polydispersity index (PI) was recorded as an index for particle size distribu-
tion in prepared formulations. PIs ranged from monodispersed, 0.000 to 1.000, where PIs
greater than 0.500 indicated a relatively broader distribution. In injectable preparations,
PIs near 0.250 are generally considered ideal (17). PIs of formulation A (0.22  0.04) and
formulation B (0.28  0.04) were most suitable for circulating NCs (Table II).
Zeta potential is an important physicochemical parameter, which can influence fac-
tors like stability of a nano-drug carrier formulation. Extremely positive or negative zeta
potential values cause larger repulsive forces, while electrostatic repulsion between parti-
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a Mean ± SE, n = 6.
cles with the same electric charge prevents aggregation of the spheres (18). Negative zeta
potential values ranging from –3 to –5 meV were observed in four formulations (Table II).
Formulation A provided the best loading for testosterone of 30% while in formulati-
on B, significantly lower testosterone loading of 13% was observed (Table I). Formulation
C and formulation D, however, carry very low drug payloads of 5 and 3%, respectively.
When compared to formulations B–D, the solvent dielectric constant of hexane in formu-
lation A was much lower, which might have contributed to higher drug loading. In the
case of fat-soluble drugs like testosterone, the solvent dielectric constant possibly pro-
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Fig. 2. PCS particle size distribution of testosterone nanocapsule formulations using: A (hexane),
B (ethyl acetate), C (dichloromethane), D (1,2-dichloroethane).
Table II. Particle size, polydispersity and zeta potential studies of different formulations in PCS
Formulation Particle size (nm)a Polydispersityb
Zeta (meV)b
potential
A 34.5 ± 1.7 0.22 ± 0.04 –5.0 ± 0.0
B 34.8 ± 2.6 0.28 ± 0.04 –4.8 ± 0.0
C 585.2 ± 4.9 1.00 ± 0.75 –3.5 ± 0.0
D 819.8 ± 13.6 1.00 ± 0.75 –3.0 ± 0.0
Mean ± SE: a n = 4, b n = 6.
vides for a reasonable degree of predictability; selection of a suitable encapsulating sol-
vent might, in general, improve molecular payloading of lipophylic drugs in hydro-po-
lymer nanocapsules.
In view of the drug payload and PCS size distribution, formulation A was chosen
for further physicochemical studies and necessary evaluations in order to arrive at a de-
sired natural androgenic hormonal drug delivery system.
The DSC and the FT-IR studies were carried out to determine whether testosterone
was incorporated in formulation A NCs in crystalline, amorphous or bound form. DSC
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Fig. 3. DSC thermograms for: a) alginate, b) testosterone,
c) formulation A (using hexane) nanocapsules.
studies revealed that the pure testosterone powder was crystalline with sharp melting at
149 °C (Fig. 3b) and the alginate polymer was amorphous showing a decomposition en-
dotherm at around 292 °C (Fig. 3a). Testosterone endotherm devoid of powder melting
was clearly observable at 149 °C in formulation A NCs (Fig. 3c) with the nanocapsule
polymer decomposition at 220 °C. The drug was therefore considered encapsulated in its
amorphous form (19) and was presumably unbound in the polymer coat.
FT-IR studies at 280 scans were recorded for the pure powdered testosterone (Fig.
4b), formulation A NCs (Fig. 4c) and the alginate powder (Fig. 4a). In FT-IR studies, the
characteristic tautomeric testosterone C=O stretching at around 1660 cm–1 was clearly
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Fig. 4. FT-IR spectra for: a) alginate (COOH at 1611cm–1), b) pure testosterone powder (C=O stretch-
ing at 1660 cm–1), c) formulation A (using hexane) nanocapsules with both testosterone (C=O
stretching at 1660 cm–1) and alginate (COOH stretching at 1611 cm–1).
distinguishable in the testosterone loaded formulation A (Fig. 4c). Additionally, O=C—H
stretching of testosterone at 2871 cm–1 was also observed unchanged in formulation A,
suggesting no drug-polymer chemical interactions in loaded NCs.
TEM is a 2D image of a 3 dimensional nanocapsule while PCS provides NCs hydro-
dyanamic diameter in terms of equivalent sphere. Transmission electron microscopy of
uranyl acetate stained formulation A NCs were spherical with a dense central core for
encapsulated testosterone (Fig. 5). Average TEM diameter for formulation A was obser-
ved to be 150 nm from 200 counts in four observation plates. TEM diameters though ap-
peared relatively larger they were within the higher ranges of PCS observations. Both
PCS and TEM are independent techniques of observation, but were sufficiently informa-
tive and complementary to each other (20).
The time dependent cumulative percentage release profile of formulation A was
studied (Fig. 6). A sustained release profile for testosterone payload was observed over a
period of 48 h. Both the size and the amount of the drug loading were known to influence
the nanocapsular drug release profile (21). Smaller particles were evidently supporting
faster the initial drug release equilibrium (22). Goodness of fit in different release kinetic
models was evaluated in order to understand the mechanism of drug release (Table III).
In general, the drug release mechanism of formulation A followed an overall zero-order
kinetics dependent only on time. Formulation A drug release rate did not, however, fit
into the concentration and time dependent first-order release mechanism model, sug-
gesting that the overall in vitro testosterone release mechanism was of payload indepen-
dent zero-order type, as expected for particular fat soluble drug carriers. As the drug
loading in formulation A was near 30%, the surface area dependent Higuchi’s dissolu-
tion model was evaluated and was found valid. The power law model (23) is a very sug-
gestive tool to study the drug release mechanism dependent on the n' value. When n' is
0.43, drug diffusion is proportional to the concentration gradient indicating Fickian dif-
fusion, while, n' value reaching 0.85 is indicative of the drug concentration gradient in-
dependent, non-Fickian, drug release mechanism. The power law was generally evalu-
ated up to 60% of the total drug release (24, 25). Testosterone release mechanism from
formulation A was evaluated and the n' value observed to be 0.36. The in vitro release
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Fig. 5. TEM micrograph of formulation A (using hexane) nanocapsules.
mechanism in formulation A was therefore taken to be following a Fickian diffusion
mechanism. Hence the preparative technique followed has a predictive ability for andro-
genic hormonal drug payloading and release.
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Fig. 6. Testosterone release profile for formulation A nanocapsules (using hexane).
Each point represents mean ± SE, n = 4.
Table III. Testosterone release mechanism from formulation A nanocapsules
Release kinetic model Zero-ordera Higuchi’s modela Power lawa
Equation Dt = k0 t Q = kH t1/2 Mt = M kP tn'
k value k0 = 0.0503 ± 0.0075 kH = (6.9 ± 0.4) x 10–5
kP = 0.2479 ± 0.0044
n' = 0.3615 ± 0.0730
R2 1.000 0.98155 0.93378
k0 – zero-order release rate constant, Dt – drug release mass at time t, Q – mass of drug release per unit surface
area at time t, kH – Higuchi’s release rate constant, Mt – mass of drug released over time t, M – mass of drug re-
leased over infinite time, kP – kinetic constant of power law, n' – release component, R – correlation coefficient
a Mean ± S.E, n = 6.
CONCLUSIONS
Natural androgenic nanocarriers in biodegradable polymer material, following a
controlled release profile, have been formulated. Significant testosterone payload in algi-
nate NCs was achieved using the food grade hexane as a drug loading solvent. The in vitro
release of testosterone from alginate nanocapsules followed a Fickian diffusion mecha-
nism. This nanocapsulation technique can be further tested for the development of dif-
ferent steroid hormonal drug carrier therapeutics.
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S A @ E T A K
Priprava i in vitro karakterizacija alginatnih nanokapsula
za polagano osloba|anje testosterona
BENOY BRATA BHOWMIK, BISWANATH SA i ARUP MUKHERJEE
U radu je opisana priprava nanokapsula za polagano osloba|anje testosterona. Na-
nokapsule su pripravljene iz biorazgradljivog hidrofilnog polimera alginata umre`avanjem
in situ. Variraju}i udio lijeka u teku}oj fazi pripravljeno je nekoliko razli~itih nanokap-
sula. Upotreba heksana kao otapala omogu}ila je visoki sadr`aj testosterona u nanokap-
sulama (30%). Prisutnost testosterona potvr|ena je pomo}u FT-IR i DSC, a za kvanti-
tativno odre|ivanje upotrebljena je HPLC metoda. Pomo}u transmisijskog elektronskog
mikroskopa utvr|eno je da su pripravljene nanokapsule sferno simetri~ne i imaju gustu
ovojnicu s ljekovitom supstancijom. Hidrodinami~ki promjer nanokapsula bio je 34,5 ±
1,7 nm (Gaussova raspodjela), a zeta potencijal –5,0 meV. Osloba|anje testosterona in vi-
tro bilo je polagano tijekom 48 sati, a slijedilo je kinetiku nultog reda. Otapalo koje je
428
B. Brata Bhowmik et al.: Preparation and in vitro characterization of slow release testosterone nanocapsules in alginates, Acta Pharm.
56 (2006) 417–429.
upotrebljeno za punjenje nanokapsula ljekovitom tvari utje~e na koli~inu ljekovite tvari i
raspodjelu veli~ine nanokapsula. Opisana metoda nanokapsuliranja mo`e se primijeniti
i na druge steroidne hormone.
Klju~ne rije~i: testosteron, nanokapsule, alginat, heksan
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